Morgan Stanley
MXCT icon

Morgan Stanley’s MaxCyte MXCT Stock Holding History

Morgan Stanley’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.54M Buy
3,694,049
+5,918
+0.2% +$5.9K ﹤0.01% 4297
2026
Q1 		$2.59M Sell
3,688,131
-745,562
-17% -$696K ﹤0.01% 4578
2025
Q4 		$6.87M Sell
4,433,693
-2,262,186
-34% -$3.61M ﹤0.01% 3937
2025
Q3 		$10.6M Sell
6,695,879
-329,584
-5% -$573K ﹤0.01% 3492
2025
Q2 		$15.3M Buy
7,025,463
+24,664
+0.4% +$59.7K ﹤0.01% 3063
2025
Q1 		$19.1M Buy
7,000,799
+2,592,546
+59% +$10.2M ﹤0.01% 2738
2024
Q4 		$18.3M Sell
4,408,253
-408,879
-8% -$1.55M ﹤0.01% 2837
2024
Q3 		$18.7M Buy
4,817,132
+177,970
+4% +$750K ﹤0.01% 2864
2024
Q2 		$18.2M Buy
4,639,162
+1,120,046
+32% +$4.82M ﹤0.01% 2769
2024
Q1 		$14.7M Buy
3,519,116
+38,106
+1% +$179K ﹤0.01% 3003
2023
Q4 		$16.4M Buy
3,481,010
+2,155,840
+163% +$8.39M ﹤0.01% 2883
2023
Q3 		$4.13M Sell
1,325,170
-296,847
-18% -$1.19M ﹤0.01% 3890
2023
Q2 		$7.45M Sell
1,622,017
-58,852
-4% -$270K ﹤0.01% 3449
2023
Q1 		$8.32M Buy
1,680,869
+120,348
+8% +$593K ﹤0.01% 3315
2022
Q4 		$8.52M Buy
1,560,521
+71,280
+5% +$437K ﹤0.01% 3233
2022
Q3 		$9.68M Sell
1,489,241
-65,599
-4% -$366K ﹤0.01% 3020
2022
Q2 		$7.35M Buy
1,554,840
+252,863
+19% +$1.25M ﹤0.01% 3397
2022
Q1 		$9.1M Sell
1,301,977
-74,248
-5% -$507K ﹤0.01% 3010
2021
Q4 		$14M Buy
1,376,225
+82,026
+6% +$881K ﹤0.01% 2545
2021
Q3 		$15.8M Buy
+1,294,199
New +$19.5M ﹤0.01% 2344

Other funds holding MXCT

CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $128M AUM
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley's MXCT Position: Q2 2026 in Review

Morgan Stanley increased its MaxCyte (MXCT) stake by 0.16% in Q2 2026, buying an estimated $5.9K and bringing the position to 3,694,049 shares worth $4.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4297.

Morgan Stanley first reported a position in MXCT in Q3 2021 and has held it in 20 quarters since. The position peaked at $19.1M in Q1 2025. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Morgan Stanley held 3,694,049 shares of MaxCyte worth $4.54M as of Q2 2026.
  • Morgan Stanley bought 5,918 MaxCyte shares in Q2 2026, an estimated $5.9K.
  • MaxCyte made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4297 holding.
  • Morgan Stanley first reported a position in MaxCyte in Q3 2021 and has held it in 20 quarters since.
  • Morgan Stanley's MaxCyte position peaked at $19.1M in Q1 2025.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.